Khondrion is advancing sonlicromanol, a first-in-class, disease-modifying small molecule for primary mitochondrial diseases (PMD), with lead focus on m.3243A>G-associated disease, the most prevalent mtDNA mutation. Sonlicromanol targets a central, upstream mechanism—mitochondria-induced ferroptosis—through a multimodal profile integrating redox modulation, radical scavenging, and anti-inflammatory activity. Across Phase 1/2 trials, the drug has shown dose-dependent PK, excellent safety, and consistent clinical signals across fatigue, motor function, cognition, and systemic symptoms. A global Phase 3 program will start in Dec 25 / Jan 26. Khondrion combines deep mechanistic expertise, proprietary biomarkers, and strong patient-derived insights to enable precision development. The company is seeking strategic partners for co-development, regional commercialisation, and lifecycle expansion into broader mitochondrial disorders.